Jonathan W. Friedberg

Jonathan W. Friedberg's AcademicInfluence.com Rankings

Philosophy

#7452

World Rank

#10671

Historical Rank

Logic

#4500

World Rank

#5806

Historical Rank

philosophy Degrees

Jonathan W. Friedberg

Biology

#10118

World Rank

#13415

Historical Rank

Immunology

#628

World Rank

#649

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Jonathan W. Friedberg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jonathan W. Friedberg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma (2017) (3053)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. (2010) (778)
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. (2014) (682)
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. (2015) (553)
Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. (2002) (420)
Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. (2002) (405)
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. (2017) (404)
Relapsed/refractory diffuse large B-cell lymphoma. (2011) (402)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (2019) (394)
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. (2008) (303)
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. (2004) (295)
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. (2013) (283)
Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. (2014) (280)
Follicular lymphoma in the United States: first report of the national LymphoCare study. (2009) (274)
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. (2007) (250)
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. (2014) (248)
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). (2013) (246)
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. (2016) (224)
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. (2009) (201)
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. (2019) (198)
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. (2014) (192)
B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. (2007) (182)
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. (2011) (180)
Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. (1999) (175)
Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). (2015) (167)
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. (2016) (165)
The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. (2022) (165)
Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. (2005) (163)
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. (2009) (155)
Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. (2012) (155)
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. (2016) (142)
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non‐Hodgkin's lymphoma (2002) (141)
Transformed follicular non-Hodgkin lymphoma. (2015) (140)
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. (2013) (137)
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. (2015) (137)
Treatment of Hodgkin lymphoma: a 50-year perspective. (2014) (127)
FDG-PET is Superior to Gallium Scintigraphy in Staging and More Sensitive in the Follow-up of Patients with de novo Hodgkin Lymphoma: A Blinded Comparison (2004) (125)
Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. (2005) (121)
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. (2007) (120)
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. (2015) (115)
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. (2010) (115)
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. (2018) (113)
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. (2015) (109)
Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. (2015) (107)
Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (2017) (105)
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. (2021) (105)
How I treat double-hit lymphoma. (2017) (103)
Breast Lymphoma Associated With Breast Implants: Two Case-reports and a Review of the Literature (2002) (102)
Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303 (2016) (101)
PET scans in the staging of lymphoma: current status. (2003) (100)
Is there an association between ocular adnexal lymphoma and infection with Chlamydia psittaci? The University of Rochester experience. (2006) (96)
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. (2018) (96)
Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. (2010) (94)
Double-hit diffuse large B-cell lymphoma. (2012) (91)
Lack of benefit of central nervous system prophylaxis for diffuse large B‐cell lymphoma in the rituximab era (2012) (87)
Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. (2017) (87)
The Bruton tyrosine kinase (BTK) inhibitor PCI‐32765 synergistically increases proteasome inhibitor activity in diffuse large‐B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib (2013) (86)
Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. (2012) (86)
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. (2008) (84)
Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma (2009) (81)
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas (2009) (79)
PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo (2014) (77)
Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. (1999) (77)
Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells (2015) (73)
Transformed non‐Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database (2013) (72)
Burkitt lymphoma in adults. (2008) (72)
CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. (2018) (72)
Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma. (2019) (71)
Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. (2017) (71)
Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma (2014) (70)
Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. (2016) (70)
Clozapine-caused eosinophilic colitis. (1995) (69)
Diffuse large B-cell lymphoma. (2008) (69)
A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). (2016) (67)
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. (2016) (67)
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL. (2017) (65)
Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. (2012) (61)
Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo (2011) (60)
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B‐cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort (2015) (60)
Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. (2017) (58)
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. (2016) (57)
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy (2014) (56)
Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1 (2016) (56)
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. (2020) (56)
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. (2013) (55)
Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. (2005) (54)
Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. (2010) (53)
Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study (2013) (52)
Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). (2011) (51)
Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial. (2020) (50)
Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease (2003) (50)
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. (2018) (50)
Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era (2015) (49)
Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma‐related mortality in elderly follicular lymphoma in the United States (2015) (49)
Second‐line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study (2019) (44)
Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL) (2011) (43)
Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis (2018) (42)
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. (2015) (42)
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab (2013) (42)
Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. (2009) (42)
Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era (2016) (41)
Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study. (2012) (41)
New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical Practice (2011) (41)
High risk of eosinophilia in women treated with clozapine. (1993) (41)
Treating Burkitt Lymphoma in Adults (2015) (41)
Randomized Phase II Trial Comparing GA101 (Obinutuzumab) with Rituximab in Patients with Relapsed CD20 Indolent B-Cell Non-Hodgkin Lymphoma: Preliminary Analysis of the GAUSS Study (2011) (41)
High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database (2012) (40)
Phase II trial of R‐CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601 (2016) (40)
High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era (2012) (39)
Initial therapeutic strategy in follicular lymphoma (FL): An analysis from the National LymphoCare Study (NLCS). (2006) (39)
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. (2020) (37)
Radiation for diffuse large B‐cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project (2015) (37)
Profound Hypogammaglobulinemia 7 Years after Treatment for Indolent Lymphoma (2008) (37)
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412 (2021) (37)
Outcomes of MYC‐associated lymphomas after R‐CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704 (2016) (37)
Racial differences in presentation and management of follicular non‐Hodgkin lymphoma in the United States (2012) (37)
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. (2008) (37)
BCL-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress (2009) (37)
ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP (2019) (36)
The Role of Bortezomib in the Treatment of Lymphoma (2007) (36)
Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline (2015) (36)
RB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL: results of SWOG Study S1106 (2017) (36)
Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†. (2014) (36)
Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT (2019) (34)
Treatment of follicular non-Hodgkin's lymphoma: the old and the new. (2008) (34)
The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma. (2001) (34)
Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. (2015) (34)
Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the Interlymph Non-Hodgkin Lymphoma Subtypes Project. (2014) (34)
Unmet needs in the first-line treatment of follicular lymphoma (2017) (34)
A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab (2013) (33)
Iodine-131 tositumomab (Bexxar®): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin’s lymphoma (2004) (32)
Burkitt lymphoma- a rare but challenging lymphoma. (2018) (32)
Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma. (2012) (32)
Comparison of referring and final pathology for patients with T‐cell lymphoma in the National Comprehensive Cancer Network (2014) (32)
ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma. (2010) (32)
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. (2015) (31)
Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL) (2008) (31)
Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. (2019) (31)
Rituximab in indolent lymphomas. (2010) (31)
The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States (2014) (31)
A Randomized Phase III Trial of ABVD Vs. Stanford V +/− Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496) (2010) (31)
A phase I/II trial of vorinostat (SAHA) in combination with rituximab‐CHOP in patients with newly diagnosed advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0806 (2018) (30)
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. (2010) (30)
Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo (2012) (30)
Long‐term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non‐Hodgkin lymphoma (2017) (29)
A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics. (2009) (29)
Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations (2017) (28)
The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study (2013) (28)
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma. (2014) (28)
Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. (2010) (28)
R‐CHOP with iodine‐131 tositumomab consolidation for advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0433 (2014) (27)
A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. (2013) (27)
Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab (2008) (26)
Transformation of marginal zone lymphoma (and association with other lymphomas). (2017) (26)
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma (2019) (26)
PCR assays detect B-lymphocyte clonality in formalin-fixed, paraffin-embedded specimens of classical hodgkin lymphoma without microdissection. (2010) (25)
Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion. (2012) (25)
High-dose therapy for follicular lymphoma. (2000) (25)
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. (2013) (25)
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520 (2016) (25)
Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604) (2015) (24)
Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States (2015) (24)
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. (2022) (24)
Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. (2002) (23)
Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL. (2005) (23)
Bendamustine, Bortezomib and Rituximab in Patients (pts) Relapsed/Refractory Indolent and Mantle Cell Non-Hodgkin Lymphoma (NHL): a Multicenter Phase II Clinical Trial. (2009) (23)
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma (2018) (23)
Salvage therapy in Hodgkin's lymphoma. (2009) (22)
Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a Phase 1b Study In Treatment-Naïve Patients With CD20-Positive B-Cell Non-Hodgkin’s Lymphoma (NHL) (2013) (22)
Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). (2014) (22)
Patterns and timing of initial relapse in patients subsequently undergoing transplantation for Hodgkin's lymphoma. (2009) (22)
T‐Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment (2017) (22)
Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. (2004) (22)
Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study (2020) (21)
Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study (2012) (21)
Early Relapse Of Follicular Lymphoma After R-CHOP Uniquely Defines Patients At High Risk For Death: An Analysis From The National Lymphocare Study (2013) (21)
Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma (2020) (21)
Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States (2016) (21)
Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years (2019) (20)
Recommendations for Clinical Trial Development in Follicular Lymphoma (2017) (20)
A case–control study of ultraviolet radiation exposure, vitamin D, and lymphoma risk in adults (2010) (20)
Rituximab for early-stage diffuse large-B-cell lymphoma. (2006) (19)
Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience. (2019) (19)
Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. (2011) (19)
Vitamin D and Non-Hodgkin Lymphoma Risk in Adults: A Review (2009) (19)
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma (2021) (18)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia (2016) (18)
Interinstitutional variation in management decisions for treatment of 4 common types of cancer: A multi-institutional cohort study. (2014) (18)
Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort (2018) (18)
A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma (2011) (18)
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas (2016) (18)
Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma. (2007) (18)
Abstract CT019: Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL) (2017) (18)
Autologous Bone Marrow Transplantation for Marginal Zone Non-Hodgkin's Lymphoma (2004) (17)
Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma. (2016) (17)
Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. (2015) (17)
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. (2006) (17)
Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. (2021) (17)
A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States (2011) (17)
Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial (2017) (16)
Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma (1999) (16)
Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R (2015) (16)
Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non‐Hodgkin lymphoma (NHL) multicenter outcomes database (2008) (15)
Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313) (2008) (15)
Fatal Phenformin-Associated Lactic Acidosis (1997) (14)
Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. (2019) (14)
Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost‐effective (2016) (14)
Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496 (2010) (14)
Bendamustine HCl (TREANDATM) Treatment Results in High Rates of Objective Response in Patients with Rituximab-Refractory and Alkylator-Refractory Indolent B-Cell Non-Hodgkin’s Lymphoma (NHL): Results from a Phase II Multicenter Single-Agent Study (SDX-105-01). (2005) (14)
Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse. (2016) (14)
POLARIX: A PHASE 3 STUDY OF POLATUZUMAB VEDOTIN (POLA) PLUS R‐CHP VERSUS R‐CHOP IN PATIENTS (PTS) WITH UNTREATED DLBCL (2019) (14)
Using the pathology report in initial treatment decisions for diffuse large B-cell lymphoma: time for a precision medicine approach. (2015) (14)
Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). (2017) (14)
Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial. (2008) (13)
Rituximab maintenance in follicular lymphoma: PRIMA (2011) (13)
PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001 (2019) (13)
Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R (2017) (13)
Targeting the follicular lymphoma microenvironment through blockade of TNFα with etanercept (2008) (13)
State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report. (2017) (13)
High-dose therapy and stem cell transplantation in follicular lymphoma (1999) (13)
POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL. (2019) (13)
Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study. (2015) (13)
RISK‐ADAPTED THERAPY IN ADULTS WITH BURKITT LYMPHOMA: UPDATED RESULTS OF a MULTICENTER PROSPECTIVE PHASE II STUDY OF DA‐EPOCH‐R (2017) (13)
Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions. (2017) (12)
SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial (2016) (12)
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma (2017) (12)
Classical Hodgkin lymphoma (2021) (12)
Hemophagocytic lymphohistiocytosis masquerading as progressive chronic lymphocytic leukemia. (2013) (12)
Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges. (2015) (12)
Progress in Advanced-Stage Follicular Lymphoma. (2018) (12)
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study. (2018) (12)
Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL). (2013) (12)
Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL) (2019) (12)
Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era. (2012) (11)
Developing New Monoclonal Antibodies for Aggressive Lymphoma (2004) (11)
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma (2008) (11)
Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1–2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database (2013) (11)
ASTCT, CIBMTR and EBMT Clinical Practice recommendations for transplant and cellular therapies in mantle cell lymphoma. (2021) (11)
Recent advances in the development of Aurora kinases inhibitors in hematological malignancies (2015) (11)
A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (2019) (11)
Gemcitabine and Other New Cytotoxic Drugs: Will Any Find Their Way Into Primary Therapy? (2010) (10)
Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy (2015) (10)
Management of marginal zone lymphoma. (2013) (10)
Follicular Lymphoma: First-Line Treatment Without Chemotherapy for Follicular Lymphoma (2015) (10)
Late Relapses After High‐dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B‐cell Lymphoma in the Rituximab Era (2017) (10)
Phase II Trial of R-CHOP Plus Bortezomib Induction Therapy Followed By Bortezomib Maintenance for Previously Untreated Mantle Cell Lymphoma: SWOG 0601 (2014) (10)
A Clinicogenetic Risk Model (m7-FLIPI) Prospectively Identifies One-Half of Patients with Early Disease Progression of Follicular Lymphoma after First-Line Immunochemotherapy (2015) (10)
SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (2020) (9)
Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study. (2013) (9)
U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881). (2014) (9)
Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701 (2021) (9)
Follicular lymphoma: State‐of‐the‐art ICML workshop in Lugano 2015 (2017) (9)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma (2020) (9)
Secondary malignancies after therapy of indolent non-Hodgkin’s lymphoma (2008) (9)
Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma (2003) (9)
Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma. (2016) (8)
THE 23‐GENE GENE EXPRESSION‐BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL (2017) (8)
Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. (2010) (8)
End of rituximab maintenance for low-tumor burden follicular lymphoma. (2014) (8)
Bendamustine Produces Durable Responses with An Acceptable Long-Term Safety Profile in Patients with Rituximab-Refractory Non-Hodgkin's Lymphoma: A Pooled Analysis. (2009) (8)
A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results (2013) (8)
Diffuse large B-cell NHL. (2006) (8)
Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL) (2011) (8)
Efficacy of lenalidomide in high‐risk diffuse large B‐cell lymphoma (2019) (7)
Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach (2018) (7)
First‐line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)‐Medicare population‐based study (2020) (7)
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis (2019) (7)
Autologous Transplantation (autoHCT) is Associated with Improved Overall Survival (OS) in Follicular Lymphoma (FL) Patients (Pts) Experiencing Early Therapy Failure after Frontline Chemo-Immunotherapy: A National Lymphocare Study (NLCS) & CIBMTR Analysis (2017) (7)
Novel agents in mantle cell lymphoma. (2012) (7)
Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496 (2011) (7)
Rational Combinations Including a Novel Syk Inhibitor, Fostamatinib Disodium (FosD) in Diffuse Large B Cell Lymphoma. (2009) (7)
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study (2020) (7)
Phase I Trial Of Carfilzomib In Combination With Vorinostat (SAHA) In Patients With Relapsed/Refractory B-Cell Lymphomas (2013) (7)
Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics (2004) (7)
[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice (2017) (7)
Potential long-term toxicities should influence the choice of therapy for indolent non-Hodgkin's lymphoma. (2006) (7)
Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients. (2020) (7)
Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients (2020) (7)
First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1. (2022) (7)
Symptomatic intracardiac diffuse large B‐cell lymphoma (2009) (7)
Fostamatinib Inhibits BCR Signaling, and Reduces Tumor Cell Activation and Proliferation in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia. (2012) (7)
The novel alkylator bendamustine HCl is active in both rituximab-refractory and rituximab-sensitive relapsed indolent NHL with acceptable toxicity (2005) (7)
A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (2020) (6)
Bexarotene Is Highly Active in the Treatment of Subcutaneous Panniculitis-Like T-Cell Lymphoma. (2005) (6)
Outcome of patients > age 40 with Burkitt lymphoma (BL) treated with aggressive chemotherapuetic regimens : Results from the international Burkitt lymphoma collaborative group (2005) (6)
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report. (2004) (6)
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma (2022) (6)
Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL) (2019) (6)
Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas (2010) (6)
Phase I Dose-Escalation Trial of BI 2536, a Polo-Like Kinase 1 Inhibitor, in Relapsed and Refractory Non-Hodgkin’s Lymphoma (2008) (6)
An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826. (2020) (6)
High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. (2016) (6)
Intra‐arterial methylprednisolone for the management of steroid‐refractory acute gastrointestinal and hepatic graft versus host disease (2011) (6)
Combination treatment approaches and novel therapies for lymphoma. (2007) (6)
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma (2021) (6)
Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas (2013) (6)
Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study (2014) (6)
R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433 (2010) (6)
A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab‐refractory iNHL (COMPLEMENT A + B study) (2021) (6)
Second-line therapy in follicular lymphoma in the United States: Report of NLCS observational study. (2011) (5)
Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial (2016) (5)
A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED‐SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA (2017) (5)
Hodgkin lymphoma: answers take time! (2011) (5)
CLL microenvironment: macro important. (2011) (5)
Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496 (2013) (5)
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection. (2011) (5)
Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results. (2018) (5)
Complications Associated With Dose‐adjusted EPOCH‐rituximab Therapy for Non‐Hodgkin Lymphoma (2018) (5)
The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (2021) (5)
Health-Related Quality of Life in Older Patients Following Diffuse Large B-Cell Lymphoma (DLBCL) Diagnosis (2012) (5)
PET positive, PET negative, or PET peeve? (2010) (5)
Interinstitutional Variation in Management Decisions for Treatment of 4 Common Types of CancerA Multi-institutional Cohort StudyInterinstitutional Variation in Cancer Management Decisions (2014) (5)
Monoclonal antibodies in lymphoma: the first decade. (2008) (5)
SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. (2021) (5)
Subclonal Mutations of TP53 Are Common in Untreated Follicular Lymphoma and Mutation Status Is Predictive of PFS When CHOP Is Combined with 131-Iodine Tositumomab but Not with Rituximab: An Analysis of SWOG S0016 (2018) (5)
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States (2018) (5)
MYC Associated and Double Protein Lymphoma: Subset Analysis of SWOG S9704 (2014) (5)
SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987) (2014) (4)
A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas. (2007) (4)
Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma. (2015) (4)
Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies (2019) (4)
Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis Of Clinical Characteristics, Treatment, Outcomes, and Prognosis In The Current Era (2013) (4)
Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis (2020) (4)
Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma. (2008) (4)
Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma. (2018) (4)
ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS. (2021) (4)
Phase I Study of Eltrombopag for Promoting Thrombopoiesis in Patients Undergoing Stem Cell Transplantation After Total Body Irradiation (2011) (4)
The emerging role of bendamustine in follicular lymphoma (2009) (4)
Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation (2019) (4)
Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016 (2016) (4)
Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma (2021) (3)
A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX). (2018) (3)
Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database (2019) (3)
A Pilot Study of Brentuximab Vedotin and AVD Chemotherapy Followed By 20 Gy Involved-Site Radiotherapy in Early Stage, Unfavorable Risk Hodgkin Lymphoma (2017) (3)
Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy. (2021) (3)
Feasibility of Interim PET-Adapted Therapy in HIV-Positive Patients with Advanced Hodgkin Lymphoma (HL): Sub-Analysis of SWOG S0816 Phase 2 Trial (2015) (3)
Adolescents with Hodgkin Lymphoma Treated on Adult and Pediatric Protocols Have Distinct Therapeutic Outcome. (2004) (3)
A Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Patients 75 Years and Older with Diffuse Large B-Cell Lymphoma (2020) (3)
AUTOLOGOUS TRANSPLANTATION IMPROVES SURVIVAL IN PATIENTS WITH FOLLICULAR LYMPHOMA EXPERIENCING EARLY THERAPY FAILURE AFTER FRONTLINE CHEMOIMMUNOTHERAPY: AN NLCS AND CIBMTR ANALYSIS (2017) (3)
Histone Deacetylase Inhibitors Potentiate the Lethality of the Irreversible Proteasome Inhibitor Carfilzomib In Mantle Cell Lymphoma Cells In Vitro and In Vivo (2010) (3)
Emerging protein kinase inhibitors for the treatment of non-Hodgkin’s lymphoma (2014) (3)
Immunotherapy for Hematologic Malignancies. (2021) (3)
Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma (2008) (3)
Support for a Possible Vaccinal Effect of Rituximab; Lymphoma Idiotype Specific T-Cell Responses in Follicular Lymphoma Patients Treated with Rituximab. (2007) (3)
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials (2022) (2)
A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806 (2015) (2)
Radioimmunotherapy for Non-Hodgkin’s Lymphoma (2004) (2)
Targeted Therapeutics for Lymphoma: Using Biology to Inform Treatment (2018) (2)
Combination Immunotherapy with a CpG Oligonucleotide and Rituximab (R) Augments the Immunological Response and Favorably Alters the Malignant Microenvironment of Follicular Lymphoma (FL). (2006) (2)
Retrospective Analysis of the Safety and Efficacy of Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Hematologic Malignancies (2012) (2)
General Biomarker Recommendations for Lymphoma. (2016) (2)
Characteristics of Patients with Stage I Follicular Lymphoma (FL) Selected for Watchful Waiting (WW) in the US: Report from the National LymphoCare Study (NLCS). (2007) (2)
Chemotherapy free treatment of indolent lymphoma (2017) (2)
The Irreversible Proteasome Inhibitor Carfilzomib Interacts Synergistically with the Selective HDAC6 Inhibitor ACY1215 in ABC- and GC-DLBCL and Mantle Cell Lymphoma Sensitive or Resistant to Bortezomib. (2012) (2)
Characteristics and Effectiveness of Rituximab (R) Maintenance Regimens Among US Patients Diagnosed with Follicular Lymphoma (FL) 2004–2007, (2011) (2)
Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium (2020) (2)
Use of maintenance rituximab (R) in the United States following R-based induction for follicular lymphoma (FL). (2010) (2)
CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment. (2005) (2)
Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis (2018) (2)
Impact of dietary supplements, obesity and treatment initiation on serum vitamin D levels in patients with lymphoma (2015) (2)
Reply to M.C. Chamberlain (2009) (2)
ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II. (2011) (2)
A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab with CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models. (2012) (2)
Bendamustine in chronic lymphocytic leukemia: the future is combination therapy (2009) (2)
Patterns of Use of FDG-PET for the Initial Staging of Follicular Lymphoma (FL) and Its Impact on Initial Treatment Strategy and Outcomes In the National Comprehensive Cancer Network (NCCN) Lymphoma Database (2010) (2)
Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma (2020) (2)
SDX-105 Demonstrates a High Response Rate as a Single-Agent with Acceptable Safety in Rituximab-Refractory, Relpased Indolent or Transformed Non-Hodgkin’s Lymphoma (NHL). (2004) (2)
Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma In the National Comprehensive Cancer Network (NCCN) Lymphoma Database (2010) (2)
Integrating Assessment of Sarcopenia into Decision-making for Allogeneic Hematopoietic Cell Transplantation: Ready for Prime Time? (2019) (2)
Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs (2019) (2)
Bortezomib and Gemcitabine in Relapsed Hodgkin Lymphoma (HL). (2007) (2)
Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS) (2010) (2)
Introduction to Genomics in Hematologic Malignancy. (2017) (2)
How I Treat How I treat double-hit lymphoma (2017) (2)
Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab for Initial Therapy of Chronic Lymphocytic Leukemia. (2023) (2)
Wormy mothers, healthy babies: case closed or conundrum? (2011) (1)
Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN (2012) (1)
Outpatient Administration of High Dose BEAM Chemotherapy As Conditioning for Autologous Stem Cell Transplantation for Lymphoma Results in Fewer Infectious Complications and Improved Survival (2014) (1)
Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC). (2020) (1)
Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma. (2023) (1)
An Oncology Renaissance. (2021) (1)
Age Differences in Disease Characteristics, Patterns of Care, and Outcomes of Follicular Lymphoma (FL) in the United States (US): Report From the National Lymphocare Study (NLCS) (2012) (1)
Prognostic Utility of Serum TARC, MDC, IL10, and Soluble CD163 Levels with Positron Emission Tomography (PET) Response-Adapted Therapy for Advanced-Stage Hodgkin Lymphoma (HL): a SWOG S0816 US Intergroup Correlative Study (2017) (1)
Retraction: Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo (2019) (1)
The Novel Proteasome Inhibitor Carfilzomib Interacts Synergistically with HDAC Inhibitors in ABC- and GC-DLBCL Cells Both in Vitro and In Vivo through Mechanisms Involving JNK Activation, NF-κB Inactivation, and DNA Damage.. (2009) (1)
ILyAD (Indolent Lymphoma and Vitamin D): A phase III double blind, prospective randomized trial to evaluate the supplemental effect of vitamin D on progression-free survival in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy. (2018) (1)
Relapsed/refractory diffuse large B-cell lymphoma: on the threshold of new therapies. (2009) (1)
Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma (2006) (1)
PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study (2013) (1)
Abstract 3531: Changes in immune cell populations in relapsed/refractory CLL patients treated with a Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in combination with Bendamustine and Rituximab (BR). (2013) (1)
Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis. (2018) (1)
Comprehensive in Vitro and in Vivo Analysis of Phosphatidylinositol-3-Kinase Delta (PI3Kδ) Inhibition Using GS-1101 (CAL-101) in Combination with Mammalian Target of Rapamycin (mTOR) Inhibition Using Temsirolimus or Everolimus in Mantle Cell Lymphoma (MCL) (2012) (1)
Reply: Interim PET Assessment of Advanced Hodgkin Lymphoma: Is It Sufficient? (2020) (1)
Diffuse follicle centre lymphoma presents with high frequency of extranodal disease (2008) (1)
A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma (2019) (1)
Potential Impact of Pathologic Review on Therapy in Non-Hodgkin’s Lymphoma (NHL): Analysis from the National Comprehensive Cancer Network (NCCN) NHL Outcomes Project. (2005) (1)
A Prospective Multicenter Phase 2 Study of Dose-Adjusted-EPOCH-R in Untreated MYC-Rearranged Aggressive B-cell Lymphoma (2019) (1)
A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (2014) (1)
Outcomes of lenalidomide in diffuse large B-cell (DLBCL) and high-grade NHL (HGBCL): A single-center retrospective analysis. (2019) (1)
NEW PROGNOSTIC SCORE INCORPORATING MTV PREDICTS TREATMENT FAILURE IN ADVANCED HODGKIN LYMPHOMA (2021) (1)
Arrhythmia Burden in Patients with Indolent Lymphoma (2020) (1)
Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816 (2020) (1)
A Phase II Intergroup Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG Study S1001 (NCT01359592) (2017) (1)
Extracorporeal Photopheresis, Pentostatin, and TBI for Reduced-Intensity Preparation: Adaptation of the Tufts Experience at a Single Transplant Center. (2005) (1)
ONGOING TRIALS (2013) (1)
Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis (2020) (1)
Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare Study (NLCS): A U.S. patient cohort treated predominantly in community practices. (2011) (1)
Prognostic Impact of Cell of Origin in Limited-Stage Diffuse Large B-Cell Lymphoma Treated With R-CHOP With or Without Radiation Therapy (2016) (1)
Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project, (2011) (1)
High-Dose Therapy and Autologous Stem Cell Transplant (HD-ASCT) for Transformed Non-Hodgkin Lymphoma (NHL) In the Rituximab Era (2010) (1)
Phase I/II study of investigational agent MLN8237 (alisertib) plus rituximab with or without vincristine in patients (pts) with relapsed/refractory (rel/ref) aggressive diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma (TFL). (2012) (1)
Extranodal Presentation in Limited Stage DLBCL As a Prognostic Marker in Three Sequential SWOG Trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592) (2021) (1)
Treatment with Full Chemotherapy Regimens in Older Adults with Hodgkin Lymphoma Improves 3-Year Overall Survival, but Less Than Half Receive Full Regimens (2019) (1)
Increased Risk of Toxicity with Novel PI3K Delta Inhibitor Combinations Compared with Standard Use in Non-Hodgkin Lymphoma Patients (2017) (1)
Toward a Cure for Follicular Lymphoma. (2020) (1)
Prospective Validation of the FLIPI: Baseline Distribution and Correlates in Newly Diagnosed Follicular Lymphoma (FL) Patients from the US: First Report of the National LymphoCare Study. (2005) (1)
High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender (2014) (1)
Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III P (2022) (0)
Reply to E. Hawkes et al. (2020) (0)
Involved Field Radiation After Autologous Stem Cell Transplant for Large B-Cell Lymphoma in the R-CHOP Era (2007) (0)
Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium (2022) (0)
Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study (2022) (0)
Issue information (2015) (0)
Sequential RCHOP, Radioimmunotherapy and Rituximab Maintenance Improves Early Outcomes in Advanced Stage Follicular Lymphoma: 5 Year Outcomes from SWOG 0801 (2016) (0)
Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis (2022) (0)
with or without chemotherapy: long-term risks and risk factors Second malignancy after Hodgkin disease treated with radiation therapy (2013) (0)
Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL) (2020) (0)
752 2 8 J a N U a R Y 2 0 1 0 I V O L U M E 1 1 5 , N U M B E R 4 Blood (0)
Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma (2014) (0)
diffuse large B-cell lymphoma treated in the rituximab era An enhanced International Prognostic Index (NCCN-IPI) for patients with (2014) (0)
HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1. (2022) (0)
Evaluation of Activation of a NCI National Clinical Trials Network (NCTN) Study S1826 for Hodgkin Lymphoma (HL) at Children's Oncology Group (COG) Institutions (2020) (0)
Stem cell transplantation in non-Hodgkin lymphomas (2013) (0)
Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence (2022) (0)
Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma (2022) (0)
Getting to the heart of the problem in treating diffuse large B-cell lymphoma (2011) (0)
Novel Monoclonal Antibodies in the of Lymphoma (2010) (0)
Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Group (2022) (0)
Flashback Foreword: Chimeric Anti-CD20 Monoclonal Antibody Therapy. (2023) (0)
Incidence and Risk Factors for Thromboembolism in Patients with Hematologic Malignancies Undergoing Allogeneic and Autologous Stem Cell Transplantation. (2004) (0)
Clinical Evaluation (2020) (0)
Extranodal presentation in limited-stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001 (2022) (0)
Adult Burkitt Lymphoma and Leukemia (2014) (0)
Chapter 17 – Large-Cell Lymphoma (2006) (0)
Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma (2015) (0)
Economic Analysis of Screening, Diagnostic, and Treatment Technologies for Cancer: Reflections and a Roadmap for Prospective Authors. (2022) (0)
Management of patients with nodular lymphocyte-predominant Hodgkin's lymphoma. (2008) (0)
High risk patients with diffuse large B cell lymphoma are not enrolled on clinical trials. (2019) (0)
Accurate reporting of adverse events in chronic lymphocytic leukemia and non-Hodgkin lymphoma. (2011) (0)
Late Relapses Following High Dose Chemotherapy and Autologous Stem Cell Transplant in Patients with Diffuse Large B Cell Lymphoma in the Rituximab Era (2014) (0)
Novel Agents for Hematologic Malignancies: An Era of Riches (2007) (0)
The Evolution of Children's Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity (2021) (0)
Abstract 5366: The small molecule Bcl-2 antagonist obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC and ABC- sub types of DLBCL cells bothin vitroandin vivo (2011) (0)
Central line-associated complications during treatment with DA-R-EPOCH therapy for NHL. (2017) (0)
Pivotal Phase 2 Trial of Kte-C19 (anti-CD19 CAR T Cells) in Patients with Refractory Aggressive NHL (ZUMA-1) (2017) (0)
Introducing Clinical Trial Updates. (2022) (0)
Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma (2018) (0)
A Proposed Prognostic Model For Overall Survival In The Oldest Old (>80 Years Old) Follicular Lymphoma Patients (2013) (0)
An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database. (2012) (0)
Understanding Treatment Decisions for Hodgkin Lymphoma: A Qualitative Study (2022) (0)
P010: Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium (2022) (0)
Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance] (2020) (0)
Long-Term Outcome of Autologous Stem Cell Transplantation (ASCT) for Hodgkin Lymphoma (HL) in the ABVD Therapeutic Era. (2007) (0)
Early Stage Large B-cell Lymphoma in the Rituximab-CHOP +/- Radiation Era: Tailored Therapy Provides Excellent Outcome (2009) (0)
1. Building a pretreatment risk-stratification model for follicular lymphoma with genomic alterations and clinical parameters (2019) (0)
The role of frailty and comorbidity in treatment (tx) of elderly patients with Hodgkin lymphoma (HL). (2019) (0)
Vitamin D, Sun Exposure, and Lymphoma Risk. (2008) (0)
Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials. (2020) (0)
Prognostic Factors Other Than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R (2021) (0)
Poster: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the P (2022) (0)
ASCO Living Guidelines: The Next Frontier. (2022) (0)
Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database. (2012) (0)
Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium. (2022) (0)
Brentuximab vedotin for the treatment of Hodgkin’s and non-Hodgkin’s lymphoma (2015) (0)
Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database. (2009) (0)
Chapter 30 – Hodgkin's Lymphoma: Diagnosis and Treatment (2006) (0)
Early Stage Diffuse Large B Cell Lymphoma (DLBCL) in the CHOP-R Era: Does Involved Field Radiation Therapy (IFRT) Impact Outcome?. (2007) (0)
Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411 (2022) (0)
ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III (2022) (0)
inducible gene expression, without significant toxicity - β / α interferon- rituximab in patients with non-Hodgkin lymphoma: increased Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and (2013) (0)
T083: The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma (2022) (0)
Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608 (2021) (0)
Overcoming Rituximab Resistance: The US Clinical Experience With Bendamustine (2007) (0)
microenvironment: macro important (2011) (0)
Abstract CT047: SD-101, a novel intratumoral class C CpG-ODN, given with low-dose radiation in patients with untreated low-grade B-cell lymphoma: interim results of a phase I trial (2016) (0)
Rare B Cell Lymphoproliferative Disorders (2012) (0)
P004: Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials (2022) (0)
HIGH‐RISK PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA ARE NOT ENROLLED ON CLINICAL TRIALS (2017) (0)
Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo (2019) (0)
JCO Turns 40. (2022) (0)
Clinical Implications of the New Molecular Knowledge for Treatment of Diffuse Large B-Cell Lymphoma (2014) (0)
Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (2021) (0)
Inhibiting TNFα with etanercept in relapsed/refractory follicular lymphoma. (2006) (0)
Consolidative Radioimmunotherapy after Chemoimmunotherapy in Patients with Histologic Transformation of Indolent Lymphoma (2014) (0)
Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study (2013) (0)
Preclinical Development Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Car fi lzomib in GC-and ABC-DLBCL Cells In Vitro and In Vivo (2012) (0)
Oral Abstract: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results Fro (2022) (0)
Concordance with National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (CPGs): A Quality of Care Tool for Newly Diagnosed Patients (pts) with Mantle Cell Lymphoma (MCL). (2006) (0)
The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL). (2020) (0)
Gray Zone Lymphoma (GZL) with Features Intermediate between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): A Pathologic Consensus Study with Patient Outcomes and Prognostication across 15 North American Centers (2017) (0)
Characteristics and Outcomes of Patients with Double-Protein Expression in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of SWOG Study S1001 (NCT01359592) (2017) (0)
CCR New Strategies New Strategies in Diffuse Large B-cell Lymphoma : Translating Findings from Gene Expression Analyses into Clinical Practice (2011) (0)
179: Allogeneic Stem Cell Transplantation for Post-Autologous Stem Cell Transplant Relapse in Hodgkin Lymphoma: Experience at a Single Center (2008) (0)
Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas. (2022) (0)
Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell Lymphoma. (2020) (0)
Bak to death with chemotherapy. (2008) (0)
Optimizing the Use of Oral Therapy in Lymphoma. (2020) (0)
Follicular Lymphoma (2020) (0)
Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma. (2023) (0)
A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY). (2022) (0)
Gray Zone Lymphoma (GZL) with Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Classical Hodgkin Lymphoma (cHL): Pathologic Classification and Clinical Outcomes from a Multicenter Consensus Study (2016) (0)
EXABS-196-ABCL Has R-CHOP Really Been Replaced as Initial Therapy of Diffuse Large B-cell Lymphoma (DLBCL)? (2022) (0)
Age Significantly Influences Presentation and Patterns of Care in Patients with Newly Diagnosed Diffuse Large Cell Lymphoma (DLCL): Collective Data from 5 Centers Participating in the National Comprehensive Center Network (NCCN) NHL Outcomes Project. (2005) (0)
Can We Use Genetic Subgroups of Lymphoma in the Design of Clinical Trials (2019) (0)
FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma (2022) (0)
Differences in disease characteristics, treatment patterns, and outcomes between men (M) and women (W) with follicular lymphoma (FL): Prospective evaluation of 2,650 U.S. patients (pts). (2014) (0)
Reply to H.J.A. Adams et al and E.A. Hawkes et al. (2017) (0)
The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium (2022) (0)
HIGH RATE OF MORBID CENTRAL LINE ASSOCIATED COMPLICATIONS DURING TREATMENT WITH DOSE‐ADJUSTED R‐EPOCH THERAPY FOR NON‐HODGKIN LYMPHOMA (2017) (0)
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey (2022) (0)
Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016 (2019) (0)
Results of the Primary Analysis of Complement A+B: A Phase III Study of Ofatumumab in Combination with Bendamustine Versus Bendamustine Alone in Patients with Indolent Non-Hodgkin's Lymphoma That Is Unresponsive Following Rituximab or Rituximab-Containing Regimen (2018) (0)
Phase I Study for Poor Prognosis Lymphoma: Modification of the “BEAM” (BCNU +Etoposide+ARA-C+Melphalan) Regimen with Escalating-Dose Melphalan (MEL) Using Amifostine (AF) Cytoprotection and Autologous Hematopoietic Stem Cell Transplantation (AHSCT). (2006) (0)
Clinical Discussant for Relapsed/Refractory Diffuse Large B Cell Lymphoma (2019) (0)
Clinical Evaluation and Management of Lymphoma (2011) (0)
Enrollment of high-risk patients with diffuse large B-cell lymphoma in clinical trials. (2017) (0)
Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis (2021) (0)
Effect of Prior Rituximab on Residence Time of I131 Tositumomab Consolidation Therapy in Patients (pts) with Non Hodgkin’s Lymphoma (NHL): Analysis of SWOG Clinical Trials. (2008) (0)
P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL (2022) (0)
Lymphocyte Predominant Hodgkin Lymphoma (2009) (0)
Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab (2019) (0)
Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis (2023) (0)
Correction (2019) (0)
Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2 (2022) (0)
Treatment of early-stage follicular lymphoma: do as I say, not as I do (2013) (0)
Seeking wisdom from the Seer (2009) (0)
Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN (2015) (0)
Mantle cell lymphoma. (2012) (0)
Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium (2022) (0)
Pentostatin, TBI and extracorporeal photopheresis for reduced-intensity preparation: Single center adaptation of the Tufts experience (2006) (0)
Reliability of data collection for the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multi-center outcomes database: A methodological approach (2007) (0)
S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1 (2022) (0)
Poor survival with high-dose chemotherapy and autologous stem cell support in double-hit and double-expressor B-cell lymphomas (2017) (0)
Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome (2014) (0)
The US Clinical Experience with Bendamustine (2009) (0)
Abstract 5041: The effect of YOCAS©® Yoga on prescription sleep medication and over-the-counter sleep medication usage in cancer survivors with impaired sleep quality (2014) (0)
Preclinical Development Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo (2011) (0)
Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis (2016) (0)
P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1 (2022) (0)
Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents (2011) (0)
Optimizing Rituximab Therapy (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jonathan W. Friedberg?

Jonathan W. Friedberg is affiliated with the following schools:

University of Arizona
McMaster University
University of Washington
Massachusetts General Hospital
University of Rochester

Jonathan W. Friedberg's Academic­Influence.com Rankings

Why Is Jonathan W. Friedberg Influential?

Jonathan W. Friedberg's Published Works

Published Works

What Schools Are Affiliated With Jonathan W. Friedberg?

Jonathan W. Friedberg's AcademicInfluence.com Rankings